Notes
cardiovascular disease
American College of Cardiology/American Heart Association
Reference
Gandra SR, et al. Cost-Effectiveness of LDL-C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States. Clinical Cardiology : 19 Apr 2016. Available from: URL: http://doi.org/10.1002/clc.22535
Rights and permissions
About this article
Cite this article
Evolocumab cost effective in patients with high CVD risk. PharmacoEcon Outcomes News 752, 14 (2016). https://doi.org/10.1007/s40274-016-3008-2
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-016-3008-2